Inclusion Criteria:  Patients must be 18 years of age or older Patients who will receive axicabtagene ciloleucel for treatment of lymphoma  Patients must have adequate end organ function to be eligible for this study as defined by the following criteria:  ECOG performance status 0-2 Hematologic function with ANC ≥ 1000, Hgb ≥ 8, Plt ≥ 50k unless there is disease related hematologic toxicity Renal function with CrCr ≥ 40 ml/min or Cr ≤ 1.5 x ULN Hepatic function with ALT/AST ≤ 2.5 x ULN, TBili ≤ 1.5 x ULN.  Exclusion Criteria:  Patients with known allergy to N-AC